Search

Your search keyword '"Young, K.H."' showing total 176 results

Search Constraints

Start Over You searched for: Author "Young, K.H." Remove constraint Author: "Young, K.H."
176 results on '"Young, K.H."'

Search Results

4. Implementing an Integrated Critical Care Curriculum to Improve Resident Education in the Medical Intensive Care Unit: A Quality Improvement Project

6. A Phase II Trial of TGFβ Type I Receptor Inhibitor, Galunisertib, plus Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer

9. IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma

17. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies

18. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program

21. HTS-based switched fiter banks and delay lines

23. Multiparametric MRI Measures Correlate with Treatment Response and CD8 T Cell Infiltrate in Phase II Study of Tgfβri Inhibitor with Chemoradiation in Locally Advanced Rectal Cancer

26. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy

27. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.

28. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma

29. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

30. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

31. Early safety, immune monitoring, and efficacy results from three patients enrolled in a Phase 2 trial of TGFÃŽÂ 2 RI inhibitor, LY2157299, with neoadjuvant 5-fluorouracil and radiation in patients with locally advanced rectal cancer

33. ETS1 PHOSPHORYLATION AT THR38 (PETS1) IS ASSOCIATED WITH CELL OF ORIGIN (COO), CELL CYCLE ACTIVATION, AND INFERIOR OUTCOME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

34. RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE AND COMBINED WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA

35. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function

36. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma

37. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma

38. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma

39. Tetraspanin CD37 protects against the development of B cell lymphoma

43. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

44. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?

45. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries

46. Evaluation of NF-kappaB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions

47. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma

48. Resolved magnetic-field structure and variability near the event horizon of Sagittarius A(star)

49. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma

50. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

Catalog

Books, media, physical & digital resources